The Lynx Group
Cholangiocarcinoma News

Cholangiocarcinoma Year in Review Introduction

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Colleagues,
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly! Most major national and international meetings, such as the American Society of Clinical Oncology (ASCO), Gastrointestinal Cancers Symposium, and European Society for Medical Oncology (ESMO), have adopted abbreviated virtual formats that delivered cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual format in terms of reach and impact, we are bringing you the Year in Review series, which seeks to summarize recent scientific advances and disseminate to clinicians in a timely and effective manner to support cancer care delivery and research.

This edition of Year in Review is focused on cholangiocarcinoma (CCA), a malignancy where targeted therapeutics have made substantial strides. Below is a quick review of some of the topics discussed in this issue, with a focus on recent advances, potentially practice-changing developments, and ongoing challenges in CCA. Increased understanding of the CCA genetic landscape has led to identification of actionable alterations such as FGFR and IDH aberrations, for which therapeutic interventions are being developed and actively investigated.

During this year, an important milestone was reached with the approval of pemigatinib, the first targeted therapy to be approved by the US Food and Drug Administration for CCA. Efficacy of pemigatinib was demonstrated in the FIGHT-202 trial, in which 107 patients with advanced CCA whose disease had progressed on or after at least 1 prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy, and the overall response rate was 36%, including 3 complete responses. The median duration of response was 9.1 months with responses lasting ≥6 months in 24 of the 38 (63%) responding patients and ≥12 months in 7 (18%) patients. Other promising FGFR inhibitors are in development. Results of the FOENIX-CCA2 phase 2, open-label clinical trial of futibatinib, an oral FGFR inhibitor, in patients with intrahepatic CCA and FGFR2 fusions or other genetic alterations, showed that futibatinib is safe and effective in this patient population. Patient-reported outcomes from the FOENIX-CCA2 trial indicate that futibatinib therapy does not adversely affect patients’ quality of life.

Infigratinib is a selective FGFR1-3 tyrosine kinase inhibitor that has also shown promising antitumor responses in patients with advanced, metastatic CCA bearing FGFR2 alterations. Biomarker analysis of the phase 2 study of infigratinib confirmed the genetic heterogeneity of CCA, including the prevalence of FGFR aberrations. Encouraged by the promising antitumor activity demonstrated in these early trials, the phase 3 PROOF trial (NCT03773302) is evaluating the efficacy and safety of infigratinib versus gemcitabine plus cisplatin as frontline therapy in patients with advanced CCA harboring FGFR2 gene rearrangements. Ivosidenib, a targeted IDH1 small-molecule inhibitor, was investigated in the phase 3, multicenter, placebo-controlled ClarIDHy trial. This study enrolled 230 subjects with pretreated, IDH1-mutated CCA and achieved its primary end point of superior progression-free survival as compared with the placebo arm. Similar exciting results were reported with BRAF and HER2/neu targeted therapies.

The demonstrated activity of immunotherapy in other tumor types has prompted evaluation of its role in CCA. First results of the multicenter phase 2 LEAP-005 trial showed promising activity of the combination of lenvatinib and pembrolizumab in advanced solid tumors, including CCA. The combination of ipilimumab and nivolumab also showed significant clinical activity in patients with microsatellite-stable biliary tract cancer. However, the addition of immunotherapy with ipilimumab and nivolumab to gemcitabine and cisplatin chemotherapy as frontline therapy was not associated with clinical benefit. A hypothesis-generating phase 2 clinical trial from Asia evaluated 3- and 4-drug immunotherapy combinations of durvalumab plus the CTLA-4 inhibitor tremelimumab, in combination with gemcitabine and cisplatin chemotherapy. A remarkably high response rate was noted with this combination in the Korean population where the study was conducted. These results warrant further studies to define the role of immunotherapy in CCA and the heterogeneity between Asian and Western subjects.

Research efforts are also focused on developing better assays for identifying genetic aberrations in primary tumor, metastatic tumor, and in liquid biopsies, with emerging data indicating that circulating free DNA may be an important noninvasive means of identifying genetic alterations with potential clinical utility in CCA. There is continued interest in identifying novel candidate genes that might be potential targets for therapeutic intervention, with results of several such efforts presented at these meetings.

We are pleased to present the highlights of these topics and more!

Milind Javle, MD

Milind Javle, MD
Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: